alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Introduction: Status of the Introduction: Status of the

Re - Evaluation of the Health Evaluation of the Health Health Effects of Atrazine Health Effects of AtrazineAnna Lowit, Ph.D.Senior Scientist, Health Effects DivisionOffice of Pesticide Programslowit.anna@epa.gov

# Atrazine Human Health Re Atrazine Human Health Re - Evaluation EvaluationzRisk Management Goal – Protect PublicHealth From Unreasonable Risks• Hazard Assessment: Determine most sensitivelifestages and endpoints, associated durationsof exposure, and dose-response relationships• Exposure Assessment: Determine residue levelsin drinking water with adequate confidenceFebruary2010April2010September20102011Epidemiologystudies: noncancerEpidemiologystudies: cancerIntegrated weightof the evidence &hazardcharacterizationfor non-cancerFrequency ofatrazinemonitoring indrinking watersources (proposedapproaches)Frequency ofatrazinemonitoring indrinking watersources (updatedanalyses)Integratedweight of theevidence forcancerPreliminaryevaluation of 

# in

vitro& 

# in vivolaboratory studies(cancer & noncancer)Incorporatingepidemiologystudies andhuman healthincident datain riskassessmentTwo atrazinecase studies 

# Atrazine SAP Meetings: Human Health Atrazine SAP Meetings: Human Health

# Atrazine Human Hazard Re Atrazine Human Hazard Re - Evaluation EvaluationzObjective & thorough review of new scienceConduct Mode of Action (MOA) framework analysis:• Key events / pathway of toxicity• Dose-response & temporal concordance• Life stage susceptibility, and• Human relevanceDetermine duration of toxicological concernCharacterize areas of confidence and uncertaintyIntegrate experimental toxicology with epidemiology into aweight-of-evidence (WOE) assessment of hazard potentialand dose-response relationships3

# Atrazine Human Exposure Re Atrazine Human Exposure Re - Evaluation: Evaluation:

Drinking Water Drinking WaterzEstimates of exposure that match theduration of toxicological concern, e.g.,Single day peaksMulti-day averages (e.g., 3, 7, 90 days, etc)zUnderstanding of confidence in the dataTemporal & spatial variabilityStatistical approaches for interpolating monitoringdata

# Atrazine Drinking Water Exposure Atrazine Drinking Water Exposure6



# After Re After Re - Evaluation Effort Evaluation EffortzIn light of the new science and feedbackfrom the Panel, the Agency willdetermine:If the risk assessment for atrazine should berevised.Whether the drinking water monitoringfrequency requirements should be changed.
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                                   1
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                         1
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                       2,021
<CURRENT-LIABILITIES>                                2,020
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                 0
<OTHER-SE>                                               1
<TOTAL-LIABILITY-AND-EQUITY>                         2,021
<SALES>                                                  0
<TOTAL-REVENUES>                                         0
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                          0
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                             0
<EPS-BASIC>                                              0
<EPS-DILUTED>                                            0

<FN>
F1    Other Stockholders' Equity in this case represents Member's equity.

F2    Total Liabilities and Stockholders' Equity in this case represents total
      liabilities and Member's equity.
</FN>



</TABLE>
###### Editorial Note on Part 55

#### Editorial Note:

Nomenclature changes to part 55 appear at 80 FR 74980, Dec. 1, 2015.

#### § 55.11 Specific exemptions.

The Commission may, upon application by an interested person, or upon its own initiative, grant such exemptions from the requirements of the regulations in this part as it determines are authorized by law and will not endanger life or property and are otherwise in the public interest.
I 

118TH CONGRESS 

2D SESSION H. R. 7187 

To modify eligibility requirements for amateur sports governing organizations. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2024 

Mr. STEUBE (for himself, Ms. HAGEMAN, Mr. TIMMONS, Mr. BIGGS, Mr. 

WEBER of Texas, Ms. BOEBERT, Mr. GOSAR, Mr. DUNCAN, Mr. 

LAMALFA, Mrs. HOUCHIN, Mr. BABIN, Mr. DUNN of Florida, Mr. 

CLYDE, Mr. TONY GONZALES of Texas, Ms. TENNEY, Mr. KUSTOFF, and 

Mr. BOST) introduced the following bill; which was referred to the Committee on the Judiciary 

A BILL 

To modify eligibility requirements for amateur sports 

governing organizations. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Protection of Women 

5 in Olympic and Amateur Sports Act’’. 

6 SEC. 2. ELIGIBILITY REQUIREMENTS. 

7 (a) DEFINITION.—Section 220501(b) of title 36, 

8 United States Code, is amended by adding at the end the 

9 following: 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7187 IH

1 ‘‘(13) ‘female’ means an individual who has, 

2 had, will have—or would have, but for a develop3 mental or genetic anomaly or historical accident— 

4 the reproductive system that at some point produces, 

5 transports, and utilizes eggs for fertilization. 

6 ‘‘(14) ‘male’ means an individual who has, had, 

7 will have—or would have, but for a developmental or 

8 genetic anomaly or historical accident—the repro9 ductive system that at some point produces, trans10 ports, and utilizes sperm for fertilization. 

11 ‘‘(15) ‘sex’ means an individual’s biological sex, 

12 either male or female.’’. 

13 (b) ELIGIBILITY.—Section 220522 of title 36, United 

14 States Code, is amended— 

15 (1) in paragraph (18), by striking ‘‘and’’ at the 

16 end; 

17 (2) in paragraph (19), by striking the period 

18 and inserting ‘‘; and’’; and 

19 (3) by adding at the end the following: 

20 ‘‘(20) prohibits a person whose sex is male from 

21 participating in an amateur athletic competition that 

22 is designated for females, women, or girls.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
[Nos. 38066-4-I; 38588-7-I.

Division One.

December 8, 1997.]

#### The State of Washington, *Respondent,*v. Anthony J. Crane, *Appellant.*The State of Washington, *Respondent,*v. Dwayne Dodgen, *Appellant.*

Appeals from judgments of the Superior Court for Snohomish County, Nos. 95-1-00593-9 and 95-1-00594-7, Anita Louise Faris and David F. Hulbert, J., entered January 12,1996. *Reversed*by unpublished opinion per Webster, J., concurred in by Becker and Cox, JJ.
Editorial Note on Part 178
Editorial Note: Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 178.3500 Glycerin, synthetic. Synthetic glycerin may be safely used as a component of articles intended for use in packaging materials for food, subject to the provisions of this section: ( a ) It is produced by the hydrogenolysis of carbohydrates, and shall contain not in excess of 0.2 percent by weight of a mixture of butanetriols.
( b ) It is used in a quantity not to exceed that amount reasonably required to produce its intended physical or technical effect, and in accordance with any limitations prescribed by applicable regulations in parts 174, 175, 176, 177, 178 and 179 of this chapter. It shall not be intended to, nor in fact accomplish, any direct physical or technical effect in the food itself.
TROIVIBETT A • T Y IVI P A N I U IVI 

- AFITMEMT O F 

^•SPORWfON 

ET OPERATIONS 

•^ ;>q o 

Federal Aviation Administration 

800 Independence Avenue, SW 

Washington, DC 20591 

Attention: Docket Clerk, ACG-430 

Wilbur Wright Building-Room 2W1000 

Subject: FAA Case Number 2009WP700222 

FAA Docket No. CP10WP004 

DMSNO.FAA-2010-1219 

ALJ-Goodwin 

2-- 50 

Aprill4,2011 

:ARn^G DOCKET 

Trombetta Corporation formally withdrav^^s our request for a hearing in the matter of Case number 

2009WP700222. We have reached a settlement with Complainant's Council Lisa Toscano for the sum 

of $5,700.00. The fine will be paid prior to the April 18, 2011 required response date per the Order to 

Show Cause. 

Please contact me for any additional questions or concerns. 

Lisa J. Toscano 

Attorney 

Office of Regional Counsel 

PO Box 92007, Los Angeles, CA 90009-2007 

Tel 310-725-7110 

Fax 310-725-6816 

The Honorable Richard C. Goodwin, Administrative Law Judge 

Office of Hearings, M-20 

U.S. Department of Transportation 

1200 New Jersey Avenue, S.E. 

East Building Ground Floor, Room E12-320 

Washington, DC 20590 

Tel 202-366-2139 

202-366-5121 

Fax 202-366-7536 % 

.^.-.Vsj .^-,-^JS 

APR 2 0 i m 

HEARING DOCKE' 

Office 262-251-5454 Fax 262-251-5757 • N88 W13901 Main Street • Suite 200 • Menomonee Falls, Wl 53051 • www.trombetta.com 

MENOMONE E FALLS , W l • M A L D E N , IVI A • HUDSON , N H • SHANGHAI , CHIN A
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.82 Early consultation. For products intended to treat life-threatening or severely-debilitating illnesses, sponsors may request to meet with FDA-reviewing officials early in the drug development process to review and reach agreement on the design of necessary preclinical and clinical studies. Where appropriate, FDA will invite to such meetings one or more outside expert scientific consultants or advisory committee members. To the extent FDA resources permit, agency reviewing officials will honor requests for such meetings ( a ) *Pre-investigational new drug (IND) meetings.* Prior to the submission of the initial IND, the sponsor may request a meeting with FDA-reviewing officials. The primary purpose of this meeting is to review and reach agreement on the design of animal studies needed to initiate human testing. The meeting may also provide an opportunity for discussing the scope and design of phase 1 testing, plans for studying the drug product in pediatric populations, and the best approach for presentation and formatting of data in the IND.
( b ) *End-of-phase 1 meetings.* When data from phase 1 clinical testing are available, the sponsor may again request a meeting with FDA-reviewing officials. The primary purpose of this meeting is to review and reach agreement on the design of phase 2 controlled clinical trials, with the goal that such testing will be adequate to provide sufficient data on the drug's safety and effectiveness to support a decision on its approvability for marketing, and to discuss the need for, as well as the design and timing of, studies of the drug in pediatric patients. For drugs for life-threatening diseases, FDA will provide its best judgment, at that time, whether pediatric studies will be required and whether their submission will be deferred until after approval. The procedures outlined in § 312.47(b)(1) with respect to end-of-phase 2 conferences, including documentation of agreements reached, would also be used for end-of-phase 1 meetings.
[53 FR 41523, Oct. 21, 1988, as amended at 63 FR 66669, Dec. 2, 1998]
October 22, 2015

Nick Whaling

7108 Anchorage Lane

Tega Cay, SC 29708

Dear Mr. Whaling:

This letter is to inform you that we are unable to process your petition for an exemption from

Title 14, Code of Federal Regulations (14 CFR). It explains why w e can not process your

request and what you should do in the next 30 days.

Why We Can No t Process Your Request

We received your August 6, 2015 exemption filed in D ocket No. FAA

- 20 15

- 3396 , but we are

unable to process your request any further. Your petiti on does no t comply with the

requirements of § 11.81 (copy enclosed). For us to consider the request any further, you must

send us all of the following:

 The specific section or sections of 14 CFR from which you seek relief, the extent of the

relief you se ek, and the reason you seek relief.

 Any additional information, views, or arguments available to support your request.

For more detailed information relating to submitting petitions for exemption, please visit

http://aes.faa.gov/petition/index.html . Thi s website helps the petitioner to meet Federal

Aviation Administration (FAA) requirements outlines in § 11.81 and helps answer any

questions you may have.

What You Should Do

If you want us to process your request any further, you must submit the requeste d information

within 30 days. Please note that § 11.63(d) requires you to send your petition for exemption at

least 120 days before the proposed effective date of the exemption.2

If We Do Not Hear From You

If we do not receive the information, we will close the docket without notifying you further. If

you have any questions you may call the 333 Information Line (202) 267

- 2999.

Sincerely,

/s/

B rittany Newton

Program Analyst, Airmen and

Airspace Rules Division

Enclosure3
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1221 Calcium propionate. ( a ) Calcium propionate (C6H10CaO4, CAS Reg. No. 4075-81-4) is the calcium salt of propionic acid. It occurs as white crystals or a crystalline solid, possessing not more than a faint odor of propionic acid. It is prepared by neutralizing propionic acid with calcium hydroxide.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 60, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an antimicrobial agent as defined in § 170.3(o)(2) of this chapter.
( 2 ) The ingredient is used in the following foods at levels not to exceed current good manufacturing practice: baked goods as defined in § 170.3(n)(1) of this chapter; cheeses as defined in § 170.3(n)(5) of this chapter; confections and frostings as defined in § 170.3(n)(9) of this chapter; gelatins, puddings, and fillings as defined in § 170.3(n)(22) of this chapter; and jams and jellies as defined in § 170.3(n)(28) of this chapter.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[49 FR 13141, Apr. 3, 1984]
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           7,120
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                          0
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                      1,464,185
<ALLOWANCE>                                     36,682
<TOTAL-ASSETS>                               2,130,927
<DEPOSITS>                                           0
<SHORT-TERM>                                   461,104
<LIABILITIES-OTHER>                            727,538
<LONG-TERM>                                    551,189
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        74,010
<OTHER-SE>                                     138,178
<TOTAL-LIABILITIES-AND-EQUITY>               2,130,927
<INTEREST-LOAN>                                140,526
<INTEREST-INVEST>                                    0
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                               140,526
<INTEREST-DEPOSIT>                                   0
<INTEREST-EXPENSE>                              41,150
<INTEREST-INCOME-NET>                           99,376
<LOAN-LOSSES>                                   36,578
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                173,600
<INCOME-PRETAX>                                 84,955
<INCOME-PRE-EXTRAORDINARY>                      84,955
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    49,375
<EPS-BASIC>                                     1.92
<EPS-DILUTED>                                     1.91
<YIELD-ACTUAL>                                   14.37
<LOANS-NON>                                          0
<LOANS-PAST>                                     2,346
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                11,246
<CHARGE-OFFS>                                   11,142
<RECOVERIES>                                     7,554
<ALLOWANCE-CLOSE>                               36,682
<ALLOWANCE-DOMESTIC>                            36,682
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
<PAGE>   1


                                                                    EXHIBIT 23.1

                         [COOPERS & LYBRAND LETTERHEAD]

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We consent to the incorporation by reference in the registration statement of
Cybex Computer Products Corporation on Form S-8 (File No. 333-10989) of our
reports dated May 1, 1998, on our audits of the consolidated financial
statements and financial statement schedule of Cybex Computer Products
Corporation as of March 31, 1997 and 1998, and for each of the three years in
the period ended March 31, 1998.

                                                    COOPERS & LYBRAND L.L.P.

Birmingham, Alabama
June 26, 1998
##### 



EXHIBIT 31.1 PURSUANT TO RULES 13a-14 AND 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934 AND
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER I, Alan H. Fishman, certify that:  1.
    
    I have reviewed this annual report on Form 10-K/A of Independence
Community Bank Corp. (the Registrant);2.
    
    Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;3.
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of
the Registrant as of, and for, the periods presented in this report;4.
    
    The Registrants other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant
and have:  (a)
    
    Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
Registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;(b)
    
    Evaluated the effectiveness of the Registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and(c)
    
    Disclosed in this report any change in the Registrants
internal control over financial reporting that occurred during the
Registrants most recent fiscal quarter (the Registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
Registrants internal control over financial reporting; and  5.
    
    The Registrants other certifying officer(s) and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the Registrants auditors and the audit committee of
Registrants board of directors (or persons performing the equivalent
functions):  (a)
    
    All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrants
ability to record, process, summarize and report financial
information; and(b)
    
    Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrants
internal control over financial reporting. Date: April 29, 2004
    /s/Alan H. FishmanAlan H. FishmanPresident and Chief Executive Officer